Therapy Areas: AIDS & HIV
New Labcorp Test Report Helps Identify Insect Stings and Improve Therapy Decisions to Combat Allergic Reactions
22 July 2022 - - US-based life sciences company Labcorp (NYSE: LH) has launched its Labcorp Clinical Decision Support interpretative test report for its Stinging Insect Component-Specific IgE Test that provides allergen test interpretation and treatment suggestions.

Over half of stinging insect patients test positive for allergic reactions to both honeybee and yellow jacket venom.

Labcorp's Stinging Insect Component-Specific IgE Testing helps identify the specific venom to which the patient is allergic and provides a more precise diagnosis to support venom immunotherapy.

Venom-specific immunotherapy is an effective treatment for venom allergy that can help protect against future reactions, minimize side effects and lower treatment costs.

The Labcorp CDS interpretative venom allergy report expands on prior reporting to provide report interpretation and uses current Allergy Practice Parameters, which are sponsored by the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology, to offer treatment suggestions.

Dr. David Golden, a leading expert on stinging insect allergies and former chair of the Stinging Insect Hypersensitivity Practice Parameter Update workgroup, collaborated with Labcorp to establish this vital report.

The Labcorp CDS interpretive report follows the Practice Parameters and provides physicians comprehensive insight on diagnostic marker interpretation, treatment suggestions and guidance for managing venom and stinging insect therapy.

Labcorp is a leading global life sciences company that provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.